1. Home
  2. CDNA vs NEO Comparison

CDNA vs NEO Comparison

Compare CDNA & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$21.70

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$8.96

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDNA
NEO
Founded
1998
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2007
2008

Fundamental Metrics

Financial Performance
Metric
CDNA
NEO
Price
$21.70
$8.96
Analyst Decision
Buy
Strong Buy
Analyst Count
6
8
Target Price
$28.00
$13.38
AVG Volume (30 Days)
773.8K
2.2M
Earning Date
04-28-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$48,324,000.00
N/A
Revenue This Year
$16.01
$10.63
Revenue Next Year
$11.31
$9.73
P/E Ratio
$427.30
N/A
Revenue Growth
18.93
N/A
52 Week Low
$10.96
$4.72
52 Week High
$23.24
$13.74

Technical Indicators

Market Signals
Indicator
CDNA
NEO
Relative Strength Index (RSI) 60.44 55.41
Support Level $16.63 $7.50
Resistance Level $23.19 $10.66
Average True Range (ATR) 1.45 0.61
MACD -0.01 0.07
Stochastic Oscillator 71.07 48.11

Price Performance

Historical Comparison
CDNA
NEO

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: